Table 6 Clinical and laboratory outcomes of patients who were given the placebo either ≤3 days of illness or later.
From: A preliminary study on efficacy of rupatadine for the treatment of acute dengue infection
Placebo Recruited ≤3 days N = 21 | Placebo Recruited >3 days N = 46 | P value | |
|---|---|---|---|
Ascites by Ultra sound scan (%) | 9 (42.8) | 9 (19.5) | 0.1 |
Extent of Ascites as measured by US Scan | |||
Mild (%) | 5 (23.8) | 3 (6.7) | 0.09 |
Moderate (%) | 4 (19.4) | 6 (13.3) | 0.07 |
Pleural effusion by Ultra Sound Scan (%) | 3 (14.3) | 2 (4.3) | 0.3 |
Haematocrit > 20% rise from baseline | 5 (23.8) | 5 (10.9) | 0.3 |
Duration of illness | |||
Median (IQR) | 7 (6 to 8.5) | 8 (6.5 to 9) | 0.3 |
Mean (SD ± ) | 7.1 (1.8) | 7.6 (1.3) | |
Given dextran (%) | 3 (14.3) | 1 (5.9) | 0.1 |
Exceeded the fluid quota (%) | 6 (28.6) | 4 (23.5) | 0.1 |
Quantity of extra fluid given | |||
Median (IQR) | 362.5 (193.8 to 545) | 300 (231.3 to 627.5) | 0.08 |
Hepatitis (ALT > 250/L) (%) | 0 (0) | 6 (13.3) | 0.2 |
High ALT (>200 U/L) (%) | 2 (9.5) | 10 (21.5) | 1.0 |
High AST (>200 U/L) (%) | 6 (28.5) | 12 (26.5) | 1.0 |
Bleeding (%) | 2 (9.5) | 4 (8.7) | 1.0 |
Low platelet counts | |||
<20 × 109/L (%) | 5 (23.8) | 9 (20) | 0.75 |
20 to 50 × 109/L (%) | 7 (33.3) | 14 (31.1) | 0.61 |
